Galenica (GALE) Corporate Presentation summary

Sales performance

• Net sales rose 4.7% to CHF 1,314 million in the first four months of 2025, with both Products & Care and Logistics & IT segments contributing to growth.

• Products & Care segment sales increased 5.3% to CHF 572 million, while Logistics & IT grew 4.8% to CHF 1,086 million.

• Retail (B2C) sales grew 4.4%, driven by local pharmacies (+4.8%) and a high generics substitution rate of 77.3%.

• Products & Brands saw strong growth in the Swiss market (+14.5%), supported by new license agreements and organic expansion.

• Wholesale sales increased 4.8%, with notable market share gains in the physicians segment.

Segment highlights

• Local pharmacies expanded by four locations, contributing to a 1.5% expansion impact.

• Pharmacies at Home sales declined by 2.5%, while Services for Professionals grew 3.5%, supported by homecare and nursing home services.

• Logistics & IT Services sales rose 6.4%, mainly from internal IT services and pre-wholesale distribution.

• International Products & Brands sales declined 5.1%, while Swiss market sales rose 14.5%.

Market context

• The Swiss pharmaceutical market grew 4.3% to CHF 2,582.2 million YTD April 2025, with local pharmacies up 5.3% and hospitals up 3.8%.

• Consumer healthcare market expanded 1.8% to CHF 933.8 million, with OTC products up 2.9% and patient care up 1.6%.

• Market share in the Swiss consumer health market reached 11.2%.

• Despite one fewer sales day, strong market growth was observed across most channels.